Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25056216 | 0.95 | ALOX15 (0.33) | KMT2ACYP11B1CYP11B2HTR2CHTR2B | |
| SCHEMBL25056267 | 0.93 | JAK2 (0.36) | KMT2A | |
| SCHEMBL25056204 | 0.91 | CYP11B1 (0.32) | CYP11B1CYP11B2PLK1CSNK2A1PLK3 | |
| SCHEMBL25056484 | 0.89 | KMT2A (0.34) | KMT2ACYP11B1CYP11B2HTR2CHTR2B | |
| SCHEMBL25056378 | 0.87 | JAK2 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL25056319 | 0.87 | ACHE (0.32) | CYP11B1CYP11B2HTR2CHTR2B | |
| SCHEMBL25056535 | 0.87 | TGFBR1 (0.30) | — | |
| SCHEMBL25056224 | 0.85 | CTSD (0.39) | KMT2A | |
| SCHEMBL25056148 | 0.84 | CYP11B1 (0.36) | KMT2ACYP11B1CYP11B2PLK1CSNK2A1 | |
| SCHEMBL25637849 | 0.82 | SIRT6 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KMT2A 3421/4885CYP11B1 2006/4885CYP11B2 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.